UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 105

Sortiert nach

Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models

Cancer research (Chicago, Ill.), 2016-05, Vol.76 (10), p.3003-3013

2016

Volltextzugriff (PDF)

Development of Novel LAT1 Targeting Small Molecules for Boron Neutron Capture Therapy (BNCT) and Potential Application for Treating Glioblastoma

Neuro-oncology (Charlottesville, Va.), 2022-10, Vol.24 (Supplement_4), p.iv5-iv5

Morrison, Kendall

2022

Volltextzugriff (PDF)

Construction of Boronophenylalanine-Loaded Biodegradable Periodic Mesoporous Organosilica Nanoparticles for BNCT Cancer Therapy

International journal of molecular sciences, 2021-02, Vol.22 (5), p.2251

2021

Volltextzugriff (PDF)

In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates

PloS one, 2014-01, Vol.9 (1), p.e83865

2014

Volltextzugriff (PDF)

The Discovery and Preclinical Development of ASG-5ME, an Antibody-Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer

Molecular cancer therapeutics, 2016-11, Vol.15 (11), p.2679-2687

2016

Volltextzugriff (PDF)

Monoclonal antibodies to six-transmembrane epithelial antigen of the prostate-1 inhibit intercellular communication In vitro and growth of human tumor xenografts In vivo

Cancer research (Chicago, Ill.), 2007-06, Vol.67 (12), p.5798-5805

2007

Volltextzugriff (PDF)

Abstract 4332: Development of AGS15E, a novel antibody drug conjugate targeting SLITRK6 for the treatment of bladder cancer

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.4332-4332

Morrison, Kendall

2013

Volltextzugriff (PDF)

Boronotyrosine, a Borylated Amino Acid Mimetic with Enhanced Solubility, Tumor Boron Delivery, and Retention for the Re-emerging Boron Neutron Capture Therapy Field

Journal of medicinal chemistry, 2023-10, Vol.66 (19), p.13809-13820

2023

Volltextzugriff (PDF)

Development of ASG-15ME, a Novel Antibody-Drug Conjugate Targeting SLITRK6, a New Urothelial Cancer Biomarker

Molecular cancer therapeutics, 2016-06, Vol.15 (6), p.1301-1310

2016

Volltextzugriff (PDF)

Biodegradable Periodic Mesoporous Organosilica (BPMO) Loaded with Daunorubicin: A Promising Nanoparticle‐Based Anticancer Drug

ChemMedChem, 2020-04, Vol.15 (7), p.593-599

2020

Volltextzugriff (PDF)

Effect of boron compounds on the biological effectiveness of proton therapy

Medical physics (Lancaster), 2022-09, Vol.49 (9), p.6098-6109

2022

Volltextzugriff (PDF)

AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML

Molecular cancer therapeutics, 2015-07, Vol.14 (7), p.1650-1660

2015

Volltextzugriff (PDF)

AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma

Clinical cancer research, 2016-04, Vol.22 (8), p.1989-1999

2016

Volltextzugriff (PDF)

Organosilica nanoparticles containing sodium borocaptate (BSH) provide new prospects for boron neutron capture therapy (BNCT): efficient cellular uptake and enhanced BNCT efficacy

Nanoscale advances, 2023-05, Vol.5 (9), p.2537-2546

2023

Volltextzugriff (PDF)

Abstract 1274: SLITRK6, the target of a novel antibody drug conjugate AGS15E, is expressed in bladder and other cancers

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.1274-1274

2013

Volltextzugriff (PDF)

Abstract 2047: Discovery and molecular characterization of AGS-15/SLITRK6 as a novel target for antibody-mediated therapeutic development in bladder cancer

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.2047-2047

2013

Volltextzugriff (PDF)

Abstract 2650: Ags67e, an anti-cd37 monomethyl auristatin e antibody (mmae) drug conjugate as a potential therapeutic for non-hodgkin's lymphoma, chronic lymphocytic leukemia and acute myeloid leukemia

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.2650-2650

2014

Volltextzugriff (PDF)

Abstract 574: AGS62P1, a novel site-specific antibody drug conjugate targeting FLT3 exhibits potent anti-tumor activity regardless of FLT3 kinase activation status

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.574-574

2016

Volltextzugriff (PDF)

Abstract 2832: Development of AGS-22M6E, a novel antibody drug conjugate (ADC) targeting Nectin-4 for the treatment of solid tumors

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.2832-2832

2011

Volltextzugriff (PDF)

Abstract 4566: AGS-1C4D4: A fully human anti-PSCA antibody inhibits tumor formation and metastasis in orthotopic models of pancreatic cancer

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.4566-4566

2011

Volltextzugriff (PDF)

Abstract 2590: Preclinical evaluation of ASG-5ME, a novel antibody-drug conjugate for pancreatic cancer

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.2590-2590

2010

Volltextzugriff (PDF)

AGS-PSCA: A FULLY HUMAN ANTIBODY TO PSCA FOR THE TREATMENT OF PANCREATIC CANCER

Pancreas, 2005-11, Vol.31 (4), p.448

2005

Volltextzugriff (PDF)

Abstract 4393: ASG-5ME is a novel antibody drug conjugate (ADC) for treating prostate cancers

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.4393-4393

2010

Volltextzugriff (PDF)

In situ hybridization using non-isotopically labelled synthetic oligonucleotide probes and their application in clinical pathology

Morrison, Kendall

1993

Volltextzugriff (PDF)

1 – 25 von 105

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(98)
Mit Volltextzugriff
(90)

Publikationsform

Sprache

Englisch
(105)
Japanisch
(15)

Erscheinungsjahr

n.n

Thema

Science & Technology
(68)
Humans
(55)
Life Sciences & Biomedicine
(55)
Female
(31)
Male
(31)
Adult
(17)
Biological And Medical Sciences
(15)
Diabetes
(15)
Animals
(14)
Medical Sciences
(14)
Adolescent
(13)
Middle Aged
(12)
General & Internal Medicine
(11)
Medicine, General & Internal
(11)
Mice
(11)
Aged
(10)
Diabetes Mellitus, Type 1 - Complications
(10)
Epidemiology
(10)
Management
(10)
Oncology
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models

Development of Novel LAT1 Targeting Small Molecules for Boron Neutron Capture Therapy (BNCT) and Potential Application for Treating Glioblastoma

Construction of Boronophenylalanine-Loaded Biodegradable Periodic Mesoporous Organosilica Nanoparticles for BNCT Cancer Therapy

In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates

The Discovery and Preclinical Development of ASG-5ME, an Antibody-Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer

Monoclonal antibodies to six-transmembrane epithelial antigen of the prostate-1 inhibit intercellular communication In vitro and growth of human tumor xenografts In vivo

Abstract 4332: Development of AGS15E, a novel antibody drug conjugate targeting SLITRK6 for the treatment of bladder cancer

Boronotyrosine, a Borylated Amino Acid Mimetic with Enhanced Solubility, Tumor Boron Delivery, and Retention for the Re-emerging Boron Neutron Capture Therapy Field

Development of ASG-15ME, a Novel Antibody-Drug Conjugate Targeting SLITRK6, a New Urothelial Cancer Biomarker

Biodegradable Periodic Mesoporous Organosilica (BPMO) Loaded with Daunorubicin: A Promising Nanoparticle‐Based Anticancer Drug

Effect of boron compounds on the biological effectiveness of proton therapy

AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML

AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma

Organosilica nanoparticles containing sodium borocaptate (BSH) provide new prospects for boron neutron capture therapy (BNCT): efficient cellular uptake and enhanced BNCT efficacy

Abstract 1274: SLITRK6, the target of a novel antibody drug conjugate AGS15E, is expressed in bladder and other cancers

Abstract 2047: Discovery and molecular characterization of AGS-15/SLITRK6 as a novel target for antibody-mediated therapeutic development in bladder cancer

Abstract 2650: Ags67e, an anti-cd37 monomethyl auristatin e antibody (mmae) drug conjugate as a potential therapeutic for non-hodgkin's lymphoma, chronic lymphocytic leukemia and acute myeloid leukemia

Abstract 574: AGS62P1, a novel site-specific antibody drug conjugate targeting FLT3 exhibits potent anti-tumor activity regardless of FLT3 kinase activation status

AGS62P1, a Novel Anti-FLT3 Antibody Drug Conjugate, Employing Site Specific Conjugation, Demonstrates Preclinical Anti-Tumor Efficacy in AML Tumor and Patient Derived Xenografts

Abstract 2832: Development of AGS-22M6E, a novel antibody drug conjugate (ADC) targeting Nectin-4 for the treatment of solid tumors

Abstract 4566: AGS-1C4D4: A fully human anti-PSCA antibody inhibits tumor formation and metastasis in orthotopic models of pancreatic cancer

Abstract 2590: Preclinical evaluation of ASG-5ME, a novel antibody-drug conjugate for pancreatic cancer

AGS-PSCA: A FULLY HUMAN ANTIBODY TO PSCA FOR THE TREATMENT OF PANCREATIC CANCER

Abstract 4393: ASG-5ME is a novel antibody drug conjugate (ADC) for treating prostate cancers

In situ hybridization using non-isotopically labelled synthetic oligonucleotide probes and their application in clinical pathology

Suchergebnisse filtern